82 results about "Recombinant vaccinia virus" patented technology

An immunotherapeutic vaccine providing antigen presenting cells that have been pulsed with a disrupted cell preparation which includes enucleated cytosol and cell membranes of cancer cells infected with a recombinant vaccinia virus encoding at least one immunostimulating molecule. In a preferred embodiment, the vaccine includes autologous dendritic / monocytic cells (DC / M) that present a mixture of antigens (present in the enucleated cytosol and cell membranes) from melanoma cell lines that have been infected with a recombinant vaccinia virus encoding IL-2. In another of the preferred embodiments, the enucleated cytosol and cell membranes are from melanoma cells harvested from the patient to be treated. A method of making the vaccine and methods of using the vaccine to stimulate an anti-cancer immune response and to treat a patient with a cancer are also described.

The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production of polypeptides, e.g. antigens or therapeutic agents, or viral vectors for gene therapy, and the use of such recombinant MVA viruses encoding antigens as vaccines.

The present invention relates to vaccines having an increased level of safety comprising recombinant vaccinia viruses containing an inactivated E3L region. The invention also relates to methods for stimulating a protective immune response in an immunized host using the vaccines of the invention. The invention is based on the discovery that vaccinia virus mutants having deletions in the E3L region exhibit dramatically reduced pathogenesis while remaining highly immunogenic. In addition, the invention relates to modified recombinant vaccinia viruses engineered to express heterologous polypeptides and the use of such viruses in vaccines designed to stimulate a protective immune response against such polypeptides in a host. The invention further relates to an interferon-sensitive recombinant vaccinia virus with broad host range wherein a salamander eIF2α is inserted into the viral genome in place of at least a portion of the E3L gene.

The present invention relates to vaccines having an increased level of safety comprising recombinant vaccinia viruses. The invention also relates to methods for stimulating a protective immune response in an immunized host using the vaccines of the invention. The vaccines and recombinant vaccinia viruses of the invention comprise a first nucleic acid comprising an expression control sequence and a second nucleic acid comprising an exogenous nucleic acid encoding a conditional replication gene product, wherein the expression control sequence is operably linked to the exogenous nucleic acid. The exogenous nucleic acid may, by its expression or non-expression, confer upon the recombinant vaccinia virus either sensitivity or dependence upon an exogenous molecule (e.g. a drug) or a condition. Importantly, to allow the recombinant vaccinia viruses of the invention to replicate normally under permissive conditions, the exogenous nucleic acid is inserted into a non-essential locus, e.g., the E2L / E3L inter-genic locus, K1L / K2L inter-genic locus, the superoxide dismutate locus, and the 7.5 K locus.

The present invention relates to methods for purification of Vaccinia viruses (VV) and / or Vaccinia virus (VV) particles, which can lead to highly pure and stable virus preparations of predominantly biologically active viruses. The invention encompasses purifying a virus preparation in a sterilized way with high efficiency and desirable yield in terms of purity, biological activity and stability, aspects advantageous for industrial production.

The present invention relates to recombinant anti-rabies vaccines and the oral administration of such vaccines to skunks and / or mongooses. Advantageously, the anti-rabies vaccine may comprise a recombinant vaccinia virus containing a rabies glycoprotein gene. The invention encompasses methods of vaccinating skunks and / or mongooses by administration of an anti-rabies vaccines which may comprise a recombinant vaccinia virus containing a rabies glycoprotein gene.

The present invention relates to a high efficiency method of expressing immunoglobulin molecules in eukaryotic cells. The invention is further drawn to a method of producing immunoglobulin heavy and light chain libraries, particularly using the trimolecular recombination method, for expression in eukaryotic cells. The invention further provides methods of selecting and screening for antigen-specific immunoglobulin molecules, and antigen-specific fragments thereof. The invention also provides kits for producing, screening and selecting antigen-specific immunoglobulin molecules. Finally, the invention provides immunoglobulin molecules, and antigen-specific fragments thereof, produced by the methods provided herein.

The invention discloses a GFP (Green Fluorescent Protein) tracing system of a vaccinia virus and an application of the system. The system disclosed by the invention is a recombinant vaccinia virus which is a recombinant virus obtained by subjecting wild-type vaccinia virus genome DNA (Deoxyribonucleic Acid) to replacement or insertion, wherein the replacement is to replace any segment of a segment a in the wild-type vaccinia virus genome DNA by a segment b; the insertion is to insert the segment b at any locus of the segment a into the wild-type vaccinia virus genome DNA, the segment a is the DNA segment shown in the sequence 1 in a sequence table; and the segment b is the DNA segment containing GFP encoding gene. The V.V. (Vaccinia Virus)-GFP disclosed by the invention can be applied to a research in parallel with a wild-type virus; and in addition, by virtue of the signal amplification effect of the GFP, the V.V. -GFP can greatly improve the virus monitoring sensitivity, provide a new concept for establishing a novel low-dosage virus subclinical infection animal model, and provide a new technical platform for the application researches on screening of anti-V.V medicines and the like.

The present invention relates to adjuvanted recombinant anti-rabies vaccines and the oral administration of such vaccines to raccoons and other wildlife. Advantageously, the anti-rabies vaccine may comprise a recombinant vaccinia virus containing a rabies glycoprotein gene. The invention encompasses methods of vaccinating raccoons and other wildlife by administration of an anti-rabies vaccines which may comprise a recombinant vaccinia virus containing a rabies glycoprotein gene, in combination with an adjuvant which increases both vaccine viscosity and efficacy. The invention provides effective oral recombinant vaccines used in oral rabies vaccination (ORV) programs for wildlife, effective at protecting raccoons, gray foxes, coyotes, and other animals.

The present invention relates to methods for purification of Vaccinia viruses (W) and / or Vaccinia virus (W) particles, which can lead to highly pure and stable virus preparations of predominantly biologically active viruses. The invention encompasses purifying a virus preparation in a sterilized way with high efficiency and desirable yield in terms of purity, biological activity and stability, aspects advantageous for industrial production.

The present invention relates to methods for purification of Vaccinia viruses (W) and / or Vaccinia virus (W) particles, which can lead to highly pure and stable virus preparations of predominantly biologically active viruses. The invention encompasses purifying a virus preparation in a sterilized way with high efficiency and desirable yield in terms of purity, biological activity and stability, aspects advantageous for industrial production.

The invention discloses an in-vivo imaging tracing system of a vaccinia virus and an application of the system. The system disclosed by the invention is a recombinant vaccinia virus which is a recombinant virus obtained by subjecting wild-type vaccinia virus genome DNA (Deoxyribonucleic Acid) to replacement or insertion, wherein the replacement is to replace any segment of a segment a in the wild-type vaccinia virus genome DNA by a segment b; the insertion is to insert the segment b at any locus of the segment a in the wild-type vaccinia virus genome DNA; the segment a is the DNA segment shown in the sequence 1 in a sequence table; and the segment b is the DNA segment containing Gaussia luciferase encoding gene. The V.V. (Vaccinia Virus)-LUC (Luciferase) disclosed by the invention can be applied to a research in parallel with a wild-type virus; and in addition, by virtue of the signal amplification effect of the Gaussia luciferase, the V.V.-LUC can greatly improve the virus monitoring sensitivity, provide a new concept for establishing a novel low-dosage virus subclinical infection animal model, and provide a new technical platform for the application researches on screening of anti-V.V medicines and the like.

The invention discloses an efficiently recombinant vaccinia virus vector without screening markers and an establishment method of the vaccinia virus vector. The TK region of vaccinia virus Tiantan strain is knocked out by CRISPR-Cas9 technology and then the processed vaccinia virus Tiantan strain is transfected with a recombinant plasmid pJ2R-EGFP-LoxP with EGFP. By fluorescent screening, a recombinant virus lacking TK and with inserted EGFP is obtained. Through calculation, the efficiency of the recombination is dozens of times higher than that of conventional homologous recombination, and anefficiently recombinant vaccinia virus vector system is established. Based on the recombinant viral vector, a screening marker, EGFP, in the recombinant viral vector is eliminated by a Cre-LoxP system. Through molecular cloning technology, a Western Blot experiment, immunofluorescence, PCR technology, etc., EGFP is accurately eliminated at a specific site of the resulting recombinant virus. The invention establishes the efficiently recombinant vaccinia virus vector system, the screening marker of the vaccinia virus vector is eliminated, and therefore the application value to vaccine vector construction, tumor immunotherapy and other aspects is improved.

The invention provides a recombinant vaccinia virus strain DIs that possesses a polynucleotide encoding a foreign antigenic protein in the non-essential gene region of the chromosome DNA and expresses the antigenic protein; and provides a highly-safe, vaccinia virus vaccine containing the recombinant virus strain DIs as the active ingredient. The invention also provides a method of using the vaccinia virus strain DIs as a vector for protein expression.

This invention provides a vaccinia virus that grows specifically in a cancer cell and damages such cancer cell and the use of such virus for treatment of cancer. Such mitogen-activated protein kinase-dependent vaccinia virus strain lacks functions of vaccinia virus growth factor (VGF) and O1L, it does not grow in normal cells but grows specifically in cancer cells, and it has oncolytic properties that specifically damage cancer cells.

The invention provides a recombinant vaccinia virus carrying an EB (epstein-barr) virus latent membrane antigen 2 gene and an application of the recombinant vaccinia virus. A preparation method of the recombinant virus comprises the steps of constructing a joint recombinant plasmid and MVA (modified vaccinia virus ankara) infection BHK-21 cell carrying an EBV (epstein-barr virus) LMP2 exogenous gene and a green fluorescin exogenous gene, and obtaining an MVA recombinant virus (MVA-LMP2A) only carrying the EBV LMP2 exogenous gene. Mouse spleen lymphocytes immunized by MVA-LMP2A are detected by an IFN (interferon)-gamma immunodotting method, and a result shows that MVA-LMP2A can well induce EBV LMP2 specific immune response generated in a body of a mouse.

The present invention discloses recombinant vaccinia virus (VV) virions that are resistant to antiviral defenses and have enhanced anti-tumor activities. In one embodiment, the recombinant VV comprise one or more variant VV proteins that have mutations at one or more neutralizing antibody epitopes, thereby conferring viral escape from the neutralizing antibodies. In another embodiment, the recombinant VV is resistant to complement-mediated neutralization due to the expression of a regulator of complement activation (e.g. CD55). In another embodiment, the recombinant VV has enhanced anti-tumor activities due to the expression of bi-specific antibodies co-targeting cancer cells and immune effector cells, or the expression of a polypeptide blocking the PD-1 pathway. The recombinant vaccinia virus virions can be used to treat cancer in a subject.